OVID - Ovid Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.0700
-0.1200 (-3.76%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.1900
Open3.2100
Bid3.05 x 1300
Ask12.30 x 1000
Day's Range3.0700 - 3.3300
52 Week Range3.0500 - 11.4500
Volume340,384
Avg. Volume87,741
Market Cap75.688M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.03
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.80
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced plans to move ahead with a single pivotal Phase 3 trial of OV101 in pediatric patients with Angelman syndrome based on its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA). If successful, the Phase 3 efficacy and safety trial called NEPTUNE is intended to support a New Drug Application (NDA) for OV101 in Angelman syndrome.

  • GlobeNewswire23 days ago

    Ovid Therapeutics Announces OV935/TAK-935 Presentations at the American Epilepsy Society 72nd Annual Meeting

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it will present two poster presentations and one oral presentation on OV935/TAK-935 at the American Epilepsy Society (AES) 72nd Annual Meeting, taking place from November 30 – December 4, 2018, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. “The oral presentation will report new preclinical work in a genetic seizure model – the Dravet syndrome mouse model – showing OV935’s potential impact on seizure incidence, frequency and severity and improvement in overall survival,” said Matthew During, M.D., D.Sc., founder and chief scientific officer of Ovid Therapeutics.

  • Granite Point Capital’s Returns, AUM, and Holdings
    Insider Monkey27 days ago

    Granite Point Capital’s Returns, AUM, and Holdings

    Warren Lammert founded Granite Point Capital, a long/short hedge fund with a focus on small-cap companies, in January 2004. The fund is headquartered in Boston, Massachusetts, and Mr. Lammert is its portfolio manager. Prior to launching his own fund, Warren Lammert honed his investment acumen for 14 years at Janus Capital Management LLC as a […]

  • GlobeNewswire29 days ago

    Ovid Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the company will present at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 11:00 a.m. EST. The conference will be held at the Lotte New York Palace. Ovid Therapeutics (OVID) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop medicines that transform the lives of patients with rare neurological disorders.

  • GlobeNewswirelast month

    Ovid Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Recent Clinical Progress

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today reported financial results for the third quarter ended September 30, 2018 and recent progress in its clinical programs. “The remaining two months of 2018 will be an active period for Ovid,” said Jeremy Levin, DPhil, MB, BChir, chairman and chief executive officer of Ovid Therapeutics. “We will meet with the FDA to discuss the next steps for OV101 in Angelman syndrome.

  • GlobeNewswire2 months ago

    Ovid Therapeutics Presents Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101 for the Treatment of Angelman Syndrome at the 65th AACAP Annual Meeting

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced additional exploratory efficacy data and analyses from the company’s Phase 2 STARS trial that further support the potential of OV101, a novel selective extrasynaptic GABAA receptor agonist that is being investigated to treat Angelman syndrome. Angelman syndrome is a life-long genetic disorder that is characterized by a variety of signs and symptoms, and for which there are no FDA-approved medicines or an established treatment paradigm. The additional efficacy data and analyses are being presented in a poster today at the American Academy of Child and Adolescent Psychiatry (AACAP) annual meeting by Alex Kolevzon, M.D., professor of psychiatry and pediatrics at the Icahn School of Medicine at Mount Sinai.

  • GlobeNewswire2 months ago

    Ovid Therapeutics Receives “Company Making a Difference Award” from CDKL5 Deficiency Disorder Community

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced it has received the 2018 CDKL5 Forum Company Making a Difference Award for initiation of the Phase 2 ARCADE trial with OV935/TAK-935, and its commitment to the CDKL5 deficiency disorder (CDD) patient community. The award was announced today in London, UK at the CDKL5 Forum, the largest annual conference on the advancement of science and therapeutic development for CDD. CDD is a rare, severe, neurological disorder that causes frequent, treatment-resistent seizures in the first few months of life.

  • GlobeNewswire2 months ago

    Ovid Therapeutics to Host Conference Call and Webcast on Thursday, October 25, at 10:30 a.m. EDT

    -- Alexander Kolevzon, M.D., to review additional data from company’s Phase 2 STARS trial with OV101 for the treatment of Angelman syndrome during the 65th American Academy of.

  • GlobeNewswire3 months ago

    Ovid Therapeutics Announces Initiation of Two Phase 2 Clinical Trials of OV935/TAK-935 for Pediatric Patients with Rare Epilepsies

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced initiations of the Phase 2 ELEKTRA and ARCADE trials for OV935/TAK-935 in pediatric patients with rare epilepsies. The company reports that the first patient has been randomized to receive either OV935 or placebo in the ELEKTRA trial and that patient screening is underway for the ARCADE trial.

  • GlobeNewswire3 months ago

    Ovid Therapeutics to Present at Two Investor Healthcare Conferences in October 2018

    NEW YORK, Sept. 19, 2018-- Ovid Therapeutics Inc., a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that ...

  • OVID THERAPEUTC Sees Hammer Chart Pattern: Time to Buy?
    Zacks3 months ago

    OVID THERAPEUTC Sees Hammer Chart Pattern: Time to Buy?

    OVID THERAPEUTC has been struggling lately, but the selling pressure may be coming to an end soon.

  • ACCESSWIRE8 months ago

    Wired News – Axsome Therapeutics Initiated Phase-2 Clinical Trial of AXS-05 in Smoking Cessation

    LONDON, UK / ACCESSWIRE / April 25, 2018 / Active-Investors.com has just released a free research report on Axsome Therapeutics, Inc. (NASDAQ: AXSM). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AXSM as the Company's latest news hit the wire. On April 23, 2018, the Company announced that it has enrolled first patient into a Phase-2 trial assessing AXS-05 for smoking cessation treatment.

  • ACCESSWIRE8 months ago

    Wired News - Clementia Commenced Phase-2 MO-Ped Trial for Palovarotene in Pediatric Patients with Multiple Osteochondromas

    Stock Monitor: Ovid Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 24, 2018 / Active-Investors.com has just released a free research report on Clementia Pharma Inc. (NASDAQ: CMTA ...